You may be interested in

Home
About
What We Do
Resources

You may be interested in

fontSizeChange
  • A+
  • A
  • A-
Menu
Home
About
What We Do
Resources

CRISPR Cas9 based genome editing for sickle cell anemia

CRISPR
Sickle Cell Disease
gene therapy
genome editing
clinical trials
HOME | CRISPR Cas9 based genome editing for sickle cell anemia
img

overview

CSIR-IGIB, under the leadership of Drs. Souvik Maiti and Debojyoti Chakraborty have developed an indigenous CRISPR-based system for correcting the Sickle Cell Disease (SCD) mutation. Funded by the Ministry of Tribal Affairs and DST, the technology is ready for clinical trials at AIIMS, New Delhi, with technical support provided for clinical-grade material production and licensing.

Photo Gallery
image
  • 6

    TRL

  • 0

    Number of units currently deployed

  • 30

    No. of days or hours of training required

Key Features

  • Patented – US Patent 11,970,699 B2 protects the technology
  • Clinical-ready – suitable for Phase 1 trials in humans
  • Supported – technical guidance available for production and licensing

Functionality

Contact Us

Debojyoti Chakraborty

CSIR Institute of Genomics and Integrative Biology

Email: debojyoti[dot]chakraborty[at]igib[dot]in
  • DataGov
  • DigitalIndia
  • IndiaGov
  • My Gov

The Government of India established the Office of the Principal Scientific Adviser (PSA) in November 1999. The PSA's office aims to provide pragmatic and objective advice to the Prime Minister and the cabinet in matters of Science and Technology.

topbutton